This re-submitted proposal seeks continued funding for the Pancreatic Cancer Genetic Epidemiology (PACGENE) Consortium, a multicenter, multidisciplinary team which has the goal to identify susceptibility genes for familial pancreatic cancer (FPC). The PACGENE Consortium has shown that coordinated case finding, family recruitment, and linkage analysis are productive: we have identified three novel regions, and are positioned to use the pedigree material to further gene discovery. The PACGENE Consortium comprises 7 data collection/analysis centers in the U.S. and Canada, 2 Cores (Data Management/Analysis and Pathology/Tissue Genotyping), and is guided by Steering and External Advisory Committees.
Our specific aims are:
AIM 1. To validate linkage findings for gene discovery with an extended, final sample of FPC families. We will: a) Develop a set of 63 new FPC pedigrees and follow up our existing cohort of FPC pedigrees to increase their informativeness;b) Perform a genomewide (~6008 single nucleotide polymorphism (SNP)) validation linkage analysis (genotyping will be sought at the Center for Inherited Disease Research (CIDR) at no cost to this grant);
AIM 2. To perform a familial case-control association study to validate SNP associations identified in other consortia studies. We will genotype 800 FPC probands and 800 unrelated family controls using a custom SNP marker panel identified by the PanScan genomewide association study of the Cohort Consortium, the Pancreatic Cancer Case-Control Consortium, and our own linkage analyses;
AIM 3. To identify the genes in candidate regions identified by linkage and association. We will: a) Fine map regions identified through linkage analyses (including chromosomes 2p, 2q, and 10q);b) Perform genomewide loss of heterozygosity allelotyping of microdissected early stage tumors (PanINs and IPMNs) from FPC probands (comparing tumor to normal), with a focus on regions of interest;c) Resequence the best candidate genes in the regions identified. Public Health Relevance: Over 37,000 new cases of pancreatic cancer will occur in the U.S. in 2007, almost all rapidly fatal. Our research will help identify the genes for FPC, furthering knowledge about the etiology of pancreatic cancer that should accelerate translation to care. Risk assessment will be improved, and identified FPC genes will lead to development of more effective strategies for early detection, prevention, and therapy.

Public Health Relevance

Over 37,000 new cases of pancreatic cancer will occur in the U.S. in 2007, almost all rapidly fatal. Our research will help identify the genes for familial pancreatic cancer (FPC), furthering knowledge about the cause(s) of pancreatic cancer that should accelerate translation to care. Risk assessment will be improved, and identified FPC genes will lead to development of more effective strategies for early detection, prevention, and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA097075-08
Application #
7813889
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Seminara, Daniela
Project Start
2002-08-01
Project End
2013-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
8
Fiscal Year
2010
Total Cost
$1,934,190
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Streicher, Samantha A; Klein, Alison P; Olson, Sara H et al. (2017) Impact of Sixteen Established Pancreatic Cancer Susceptibility Loci in American Jews. Cancer Epidemiol Biomarkers Prev 26:1540-1548
Grant, Robert C; Denroche, Robert E; Borgida, Ayelet et al. (2017) Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology :
Howell, Lisa A; Brockman, Tabetha A; Sinicrope, Pamela S et al. (2016) Receptivity and Preferences for Lifestyle Programs to Reduce Cancer Risk among Lung Cancer Family Members. Adv Cancer Prev 1:
Childs, Erica J; Chaffee, Kari G; Gallinger, Steven et al. (2016) Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev 25:1185-91
Petersen, Gloria M (2016) Familial pancreatic cancer. Semin Oncol 43:548-553
Notta, Faiyaz; Chan-Seng-Yue, Michelle; Lemire, Mathieu et al. (2016) A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538:378-382
Smith, Alyssa L; Alirezaie, Najmeh; Connor, Ashton et al. (2016) Candidate DNA repair susceptibility genes identified by exome sequencing in high-risk pancreatic cancer. Cancer Lett 370:302-12
Roberts, Nicholas J; Norris, Alexis L; Petersen, Gloria M et al. (2016) Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov 6:166-75
McWilliams, Robert R; Maisonneuve, Patrick; Bamlet, William R et al. (2016) Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis. Pancreas 45:311-6
Zhen, David B; Rabe, Kari G; Gallinger, Steven et al. (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569-77

Showing the most recent 10 out of 69 publications